2026 Q2 -tulosraportti
51 päivää sitten
‧48 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 417 | - | - | ||
| 120 | - | - | ||
| 140 | - | - | ||
| 143 | - | - | ||
| 24 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 22.10. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 22.7. | ||
2026 Q1 -tulosraportti 23.4. | ||
2025 Q4 -tulosraportti 11.2. | ||
2025 Q3 -tulosraportti 30.10.2025 | ||
2025 Q2 -tulosraportti 17.7.2025 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·10 t sittenI've taken a tiny-tiny-micro-position in Glycorex - just to have another small leg in the transplantation market. GAK 1.35. Established on the market but uncertain if there is a profitable market for them. They are struggling a bit to scale the business - now we'll see. Remember, buy only based on your own analyses- I have Hansa at GAK 90+ 😝
·1 päivä sittenScenario where 48.22 is the top after a rise from 23.52. Note! Not a forecast or investment advice. A normal larger pullback could land somewhere around 38–36, while a really strong retracement could take it towards 33. Below 38.78 on a clear close, the picture starts to deteriorate. Then I look towards: 35.88 then 32.96 thereafter 29.18 The 50 %-level at 35.88 is particularly important. If the price falls there and then fails to regain 38–39, it starts to look more like the rise from 23.52 is actually finished." And if 32.96 is also broken with clear price structure, then it is a very deep retracement and the risk increases sharply for a test of 29.18. The negative scenario is: 48.22 top → 42.40 broken → 40.74 broken → 38.78 broken Then I would no longer consider the decline as a normal small pullback. Then 35.88 is my first larger target and thereafter 32.96. Below 32.96, 29.18 becomes interesting. Bullish would be: 48.22 → pullback to 42–43 → higher low → above 48.22 48.22 breakout with volume → 54.0–54.9 → 57.6 → 60.5 → 63.5 My opinion and not advice.
That a temporary downturn comes after a larger upturn, considering the global situation and a, in recent days, not extraordinary, increased short selling, is nothing strange in itself and more likely than it not being the case. That you would show up once again after a period of absence was also no surprise. Your appearances always come during a downturn and this downturn is nothing but a great buying opportunity in the stock. Perhaps you should take advantage of it? Regardless, it is the case that you act on various forums - for example tpå Avanza, with the aim of driving down the stock. Perhaps you could sometime elaborate on how you view long-term facts in Hansa B, considering what the CEO has presented regarding gene therapy, the impending FDA decision, the history/experience of the company's management, what analysts say, and most importantly of all, the results of the drug that Hansa Biopharma has produced. All of which is the reason you actually spend your time trying to buy the stock cheaply. If you are in the stock now, it is because you value the stock based on these facts. A piece of advice from me regarding the development of the stock price is that it will soon be heading up towards + 45....a.quite predictable advice....- ·3.9.Regarding gene therapy - Ongoing projects in addition to Renée's information about broadening the gene therapy business Généthon (Crigler-Najjar syndrome): The clinical phase 2 study (GNT-018-IDES) evaluates imlifidase as pre-treatment before gene therapy GNT-0003. The next major milestone is expected in the second half of 2026, when patient recruitment for the study is estimated to be fully completed. This will be followed by data analysis before moving on to registration-enabling studies. Sarepta Therapeutics (Duchenne muscular dystrophy): The initial clinical phase 1 study (where patients with antibodies were successfully pre-treated with imlifidase before receiving gene therapy) has been completed. Strategic discussions are currently underway regarding the next steps and the design of future clinical studies to advance the combination treatment towards the market. (Hansa’s financial participation Potential total deal value for Hansa amounts toup to USD ~400m plus royalties and incremental imlifidase sales - excerpt from presentation see link below ) AskBio (Pompe disease): This collaboration is at an earlier stage where the companies are evaluating the possibility of using imlifidase to enable gene therapy for Pompe disease. The collaboration with AskBio (entered into in 2022) represents a clear broadening of Hansa's indication area within gene therapy. By entering Pompe disease, Hansa showed that their enzyme platform (imlifidase) is not only limited to muscle diseases (like the collaboration with Sarepta in Duchenne muscular dystrophy), but can be applied to entirely new indications. Here below you can read, there is guaranteed more current information, but still interesting : https://www.hansabiopharma.com/files/Presentations/2021/20211104-HNSA-HCA-event-Gene-Therapy-FINAL.pdf
That thing with AskBio seems really interesting. If they choose to proceed to a full development and commercialization license, Hansa will get a new structure with milestones and royalties. The Sarepta agreement also shows what economic potential such a setup can have. At the same time, we have Généthon in phase 2, and now Renée says they want to further broaden the gene therapy side. A lot is starting to happen there. - ·2.9.My opinion and not advice 👇
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 481 774 | 481 774 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 481 774 | 481 774 | 0 | 0 |
2026 Q2 -tulosraportti
51 päivää sitten
‧48 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·10 t sittenI've taken a tiny-tiny-micro-position in Glycorex - just to have another small leg in the transplantation market. GAK 1.35. Established on the market but uncertain if there is a profitable market for them. They are struggling a bit to scale the business - now we'll see. Remember, buy only based on your own analyses- I have Hansa at GAK 90+ 😝
- ·1 päivä sittenScenario where 48.22 is the top after a rise from 23.52. Note! Not a forecast or investment advice. A normal larger pullback could land somewhere around 38–36, while a really strong retracement could take it towards 33. Below 38.78 on a clear close, the picture starts to deteriorate. Then I look towards: 35.88 then 32.96 thereafter 29.18 The 50 %-level at 35.88 is particularly important. If the price falls there and then fails to regain 38–39, it starts to look more like the rise from 23.52 is actually finished." And if 32.96 is also broken with clear price structure, then it is a very deep retracement and the risk increases sharply for a test of 29.18. The negative scenario is: 48.22 top → 42.40 broken → 40.74 broken → 38.78 broken Then I would no longer consider the decline as a normal small pullback. Then 35.88 is my first larger target and thereafter 32.96. Below 32.96, 29.18 becomes interesting. Bullish would be: 48.22 → pullback to 42–43 → higher low → above 48.22 48.22 breakout with volume → 54.0–54.9 → 57.6 → 60.5 → 63.5 My opinion and not advice.That a temporary downturn comes after a larger upturn, considering the global situation and a, in recent days, not extraordinary, increased short selling, is nothing strange in itself and more likely than it not being the case. That you would show up once again after a period of absence was also no surprise. Your appearances always come during a downturn and this downturn is nothing but a great buying opportunity in the stock. Perhaps you should take advantage of it? Regardless, it is the case that you act on various forums - for example tpå Avanza, with the aim of driving down the stock. Perhaps you could sometime elaborate on how you view long-term facts in Hansa B, considering what the CEO has presented regarding gene therapy, the impending FDA decision, the history/experience of the company's management, what analysts say, and most importantly of all, the results of the drug that Hansa Biopharma has produced. All of which is the reason you actually spend your time trying to buy the stock cheaply. If you are in the stock now, it is because you value the stock based on these facts. A piece of advice from me regarding the development of the stock price is that it will soon be heading up towards + 45....a.quite predictable advice....
- ·3.9.Regarding gene therapy - Ongoing projects in addition to Renée's information about broadening the gene therapy business Généthon (Crigler-Najjar syndrome): The clinical phase 2 study (GNT-018-IDES) evaluates imlifidase as pre-treatment before gene therapy GNT-0003. The next major milestone is expected in the second half of 2026, when patient recruitment for the study is estimated to be fully completed. This will be followed by data analysis before moving on to registration-enabling studies. Sarepta Therapeutics (Duchenne muscular dystrophy): The initial clinical phase 1 study (where patients with antibodies were successfully pre-treated with imlifidase before receiving gene therapy) has been completed. Strategic discussions are currently underway regarding the next steps and the design of future clinical studies to advance the combination treatment towards the market. (Hansa’s financial participation Potential total deal value for Hansa amounts toup to USD ~400m plus royalties and incremental imlifidase sales - excerpt from presentation see link below ) AskBio (Pompe disease): This collaboration is at an earlier stage where the companies are evaluating the possibility of using imlifidase to enable gene therapy for Pompe disease. The collaboration with AskBio (entered into in 2022) represents a clear broadening of Hansa's indication area within gene therapy. By entering Pompe disease, Hansa showed that their enzyme platform (imlifidase) is not only limited to muscle diseases (like the collaboration with Sarepta in Duchenne muscular dystrophy), but can be applied to entirely new indications. Here below you can read, there is guaranteed more current information, but still interesting : https://www.hansabiopharma.com/files/Presentations/2021/20211104-HNSA-HCA-event-Gene-Therapy-FINAL.pdfThat thing with AskBio seems really interesting. If they choose to proceed to a full development and commercialization license, Hansa will get a new structure with milestones and royalties. The Sarepta agreement also shows what economic potential such a setup can have. At the same time, we have Généthon in phase 2, and now Renée says they want to further broaden the gene therapy side. A lot is starting to happen there.
- ·2.9.My opinion and not advice 👇
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 417 | - | - | ||
| 120 | - | - | ||
| 140 | - | - | ||
| 143 | - | - | ||
| 24 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 22.10. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 22.7. | ||
2026 Q1 -tulosraportti 23.4. | ||
2025 Q4 -tulosraportti 11.2. | ||
2025 Q3 -tulosraportti 30.10.2025 | ||
2025 Q2 -tulosraportti 17.7.2025 |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 481 774 | 481 774 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 481 774 | 481 774 | 0 | 0 |
2026 Q2 -tulosraportti
51 päivää sitten
‧48 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 22.10. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 22.7. | ||
2026 Q1 -tulosraportti 23.4. | ||
2025 Q4 -tulosraportti 11.2. | ||
2025 Q3 -tulosraportti 30.10.2025 | ||
2025 Q2 -tulosraportti 17.7.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·10 t sittenI've taken a tiny-tiny-micro-position in Glycorex - just to have another small leg in the transplantation market. GAK 1.35. Established on the market but uncertain if there is a profitable market for them. They are struggling a bit to scale the business - now we'll see. Remember, buy only based on your own analyses- I have Hansa at GAK 90+ 😝
- ·1 päivä sittenScenario where 48.22 is the top after a rise from 23.52. Note! Not a forecast or investment advice. A normal larger pullback could land somewhere around 38–36, while a really strong retracement could take it towards 33. Below 38.78 on a clear close, the picture starts to deteriorate. Then I look towards: 35.88 then 32.96 thereafter 29.18 The 50 %-level at 35.88 is particularly important. If the price falls there and then fails to regain 38–39, it starts to look more like the rise from 23.52 is actually finished." And if 32.96 is also broken with clear price structure, then it is a very deep retracement and the risk increases sharply for a test of 29.18. The negative scenario is: 48.22 top → 42.40 broken → 40.74 broken → 38.78 broken Then I would no longer consider the decline as a normal small pullback. Then 35.88 is my first larger target and thereafter 32.96. Below 32.96, 29.18 becomes interesting. Bullish would be: 48.22 → pullback to 42–43 → higher low → above 48.22 48.22 breakout with volume → 54.0–54.9 → 57.6 → 60.5 → 63.5 My opinion and not advice.That a temporary downturn comes after a larger upturn, considering the global situation and a, in recent days, not extraordinary, increased short selling, is nothing strange in itself and more likely than it not being the case. That you would show up once again after a period of absence was also no surprise. Your appearances always come during a downturn and this downturn is nothing but a great buying opportunity in the stock. Perhaps you should take advantage of it? Regardless, it is the case that you act on various forums - for example tpå Avanza, with the aim of driving down the stock. Perhaps you could sometime elaborate on how you view long-term facts in Hansa B, considering what the CEO has presented regarding gene therapy, the impending FDA decision, the history/experience of the company's management, what analysts say, and most importantly of all, the results of the drug that Hansa Biopharma has produced. All of which is the reason you actually spend your time trying to buy the stock cheaply. If you are in the stock now, it is because you value the stock based on these facts. A piece of advice from me regarding the development of the stock price is that it will soon be heading up towards + 45....a.quite predictable advice....
- ·3.9.Regarding gene therapy - Ongoing projects in addition to Renée's information about broadening the gene therapy business Généthon (Crigler-Najjar syndrome): The clinical phase 2 study (GNT-018-IDES) evaluates imlifidase as pre-treatment before gene therapy GNT-0003. The next major milestone is expected in the second half of 2026, when patient recruitment for the study is estimated to be fully completed. This will be followed by data analysis before moving on to registration-enabling studies. Sarepta Therapeutics (Duchenne muscular dystrophy): The initial clinical phase 1 study (where patients with antibodies were successfully pre-treated with imlifidase before receiving gene therapy) has been completed. Strategic discussions are currently underway regarding the next steps and the design of future clinical studies to advance the combination treatment towards the market. (Hansa’s financial participation Potential total deal value for Hansa amounts toup to USD ~400m plus royalties and incremental imlifidase sales - excerpt from presentation see link below ) AskBio (Pompe disease): This collaboration is at an earlier stage where the companies are evaluating the possibility of using imlifidase to enable gene therapy for Pompe disease. The collaboration with AskBio (entered into in 2022) represents a clear broadening of Hansa's indication area within gene therapy. By entering Pompe disease, Hansa showed that their enzyme platform (imlifidase) is not only limited to muscle diseases (like the collaboration with Sarepta in Duchenne muscular dystrophy), but can be applied to entirely new indications. Here below you can read, there is guaranteed more current information, but still interesting : https://www.hansabiopharma.com/files/Presentations/2021/20211104-HNSA-HCA-event-Gene-Therapy-FINAL.pdfThat thing with AskBio seems really interesting. If they choose to proceed to a full development and commercialization license, Hansa will get a new structure with milestones and royalties. The Sarepta agreement also shows what economic potential such a setup can have. At the same time, we have Généthon in phase 2, and now Renée says they want to further broaden the gene therapy side. A lot is starting to happen there.
- ·2.9.My opinion and not advice 👇
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 417 | - | - | ||
| 120 | - | - | ||
| 140 | - | - | ||
| 143 | - | - | ||
| 24 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 481 774 | 481 774 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 481 774 | 481 774 | 0 | 0 |